Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Get access
Powerful Medical
•
1. October 2024
•
1 min to read
  • Multicenter Clinical Investigation

Time for a Diagnostic Paradigm Shift From STEMI/​NSTEMI to OMI/​NOMI (DIFOCCULT-3)

Link to Publication

Summary

DIFOCCULT-3 is a randomized controlled study actively enrolling patients across 18 sites in Turkey. It evaluates AI-assisted ECG interpretation in detecting high-risk heart attack patterns.

By comparing traditional STEMI/NSTEMI classification with an occlusion/non-occlusion (OMI/NOMI) model, the trial aims to improve acute coronary occlusion detection. The primary composite endpoint includes all-cause mortality and all-cause re-hospitalization at 1-year follow-up, assessing its impact on long-term patient outcomes.

Study DesignRandomized Controlled Trial (RCT)
StatusEnrolling patients
Countries / Sites1 (Turkey) / 18
Study StartOctober 1, 2024
Primary Completion (estimated)October 1, 2025
Enrollment (target)6,000
clinicaltrials.gov ID NCT06570759

Link to Publication
Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

All Publications
  • Study
  • Circulation: Cardiovascular Interventions
  • November 10, 2025

Association Between Artificial Intelligence Detected Features on the ECG and Presence of Microvascular Obstruction

This study tested whether artificial intelligence (AI)–extracted electrocardiogram (ECG) features can identify microvascular obstruction (MVO) after reperfusion in anterior ST‑segment elevation myocardial infarction (STEMI). Using pre‑ and post‑percutaneous coronary intervention (PCI) ECGs and a logistic‑regression model built on PMcardio (API v2.5), the AI approach predicted CMR‑confirmed MVO with an AUC of 0.83, 94% specificity, and 60% sensitivity; the figure reports ~76% overall accuracy. By emphasizing high specificity, the model aims to flag patients very likely to harbor MVO when cardiac MRI is impractical, enabling rapid risk stratification at the point of care.
  • Study
  • JACC Cardiovascular Interventions
  • October 28, 2025

AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry

In a large, multi-center evaluation presented as Late-Breaking Science at the TCT 2025 conference, investigators assessed the diagnostic accuracy of the Queen of Hearts™ AI algorithm for ST-segment elevation myocardial infarction (STEMI) detection in emergency care. The study compared AI-enhanced ECG interpretation against standard triage protocols across three U.S. PCI centers, encompassing more than 1,000 patients who activated emergent reperfusion pathways. Published in JACC: Cardiovascular Interventions, the results demonstrated significantly improved accuracy and reduced false activations when using AI-driven analysis.
More articles

Join over 100,000 healthcare professionals who are already taking advantage of AI

Download PMcardio app on the Apple App Store
Get PMcardio app on Google Play Store

Ready to get started?

Get access

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s certified PMcardio platform revolutionizes the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

MedTech Innovator 2025 Finalist badge in white.
Logo of Next Gen EU
Logo of Next Gen EU
MedTech Innovator 2025 Finalist badge in white.

Products

Company

Resources

Legal

Envelope Linkedin-in Instagram Facebook-f

© Powerful Medical 2025

Privacy

&

Cookies

Legal

Powerful Medical, Inc. | PMcardio and the PMcardio logo are registered trademarks of Powerful Medical. Additionally, Queen of Hearts is claimed as a trademark of Powerful Medical.

 

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Get access